蚓激酶胶囊与噻氯匹定治疗冠心病心绞痛的比较

目的 :探讨蚓激酶胶囊与噻氯匹定治疗冠心病心绞痛的疗效。方法 :冠心病心绞痛病人 50例 ,其中 30例 (男性 16例 ,女性 14例 ;年龄 6 3a±s 11a)用蚓激酶胶囊 0 .4 g ,po ,tid。另外 2 0例 (男性 12例 ,女性 8例 ;年龄 6 2a± 10a)用噻氯匹定片0 .2 5g ,po ,bid。均连用 4wk。结果 :蚓激酶组临床有效率及心电图改善率分别为 87%与 53% ;噻氯匹定组分别为 85%与 50 % ;2组比较P值均 >0 .0 5。2组对全血粘度及血小板聚集率都有明显改善作用(P <0 .0 1) ,2药均未发现不良反应。结论 :蚓激酶与噻氯匹定治疗冠心病心绞痛疗效均较好 ,且安全。

Lumbrokinase capsule vs ticlopidine in treating coronary artery disease with angina pectoris

AIM: To study the clinical efficacy of lumbrokinase and ticlopidine in the treatment of coronary artery disease with angina pectoris. METHODS: Fifty pateints of coronary artery disease with angina pectoris were divided into 2 groups. Lumbrokinase group, 30 patients (M 16, F 14;age 63 a± s 11 a) were received lumbrokinase capsule 0.4 g, po ,tid for 4 wk. Ticlopidine group, 20 patients (M 12, F 8; age 62 a±10 a), were received ticlopidine 0.25 g, po ,bid for 4 wk. RESULTS: Clinical effective rate and ECG effective rate were 87% and 53% in lumbrokinase group, 85% and 50% in ticlopidine group respectively. There was no significant difference between the two groups ( P >0.05). Blood viscosity and platelet aggregation rate of both groups were remarkably improved. ( P <0.01). CONCLUSION: Lumbrokinase and ticlopidine in treating coronary artery disease with angina pectoris are effective and safe.